SAN

77.09

+4.37%↑

ARGX

728

+2.56%↑

SHL.DE

34.73

+2.6%↑

PHIA

22.63

+2.91%↑

FRE

36.76

+1.38%↑

SAN

77.09

+4.37%↑

ARGX

728

+2.56%↑

SHL.DE

34.73

+2.6%↑

PHIA

22.63

+2.91%↑

FRE

36.76

+1.38%↑

SAN

77.09

+4.37%↑

ARGX

728

+2.56%↑

SHL.DE

34.73

+2.6%↑

PHIA

22.63

+2.91%↑

FRE

36.76

+1.38%↑

SAN

77.09

+4.37%↑

ARGX

728

+2.56%↑

SHL.DE

34.73

+2.6%↑

PHIA

22.63

+2.91%↑

FRE

36.76

+1.38%↑

SAN

77.09

+4.37%↑

ARGX

728

+2.56%↑

SHL.DE

34.73

+2.6%↑

PHIA

22.63

+2.91%↑

FRE

36.76

+1.38%↑

Inicio・Lista de Acciones・Pharma Mar SA

P
Pharma Mar SA

Abierto

96.3 1.74

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

92.15

Máximo

94.6

Métricas clave
By Trading Economics
Ingresos	-58M 1.6M
Ventas	-48M 43M
P/B Media del Sector	21.191 49.888
BPA	0.088
Margen de beneficios	3.725
Empleados	505
EBITDA	-40M 2.7M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+27.25% upside

Dividendos
By Dow Jones
Próximas Ganancias	29 jul 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	40M 1.7B
Apertura anterior	94.56
Cierre anterior	96.3

Pharma Mar SA Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

4 jun 2026, 21:51 UTC

Principales Movimientos del Mercado

Merlin Shares Rally After Defense Department's Design Review Wraps

4 jun 2026, 23:46 UTC

Charlas de Mercado

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4 jun 2026, 23:44 UTC

Charlas de Mercado

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4 jun 2026, 23:42 UTC

Adquisiciones, fusiones, absorciones

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4 jun 2026, 23:41 UTC

Adquisiciones, fusiones, absorciones

Energy Resources of Australia to Enter Trading Halt

4 jun 2026, 23:34 UTC

Charlas de Mercado

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4 jun 2026, 23:31 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

4 jun 2026, 23:31 UTC

Charlas de Mercado

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4 jun 2026, 23:31 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

4 jun 2026, 23:08 UTC

Charlas de Mercado

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4 jun 2026, 22:41 UTC

Charlas de Mercado

Australia Shares Set to Rise at the Open -- Market Talk

4 jun 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

4 jun 2026, 20:44 UTC

Adquisiciones, fusiones, absorciones

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4 jun 2026, 20:16 UTC

Charlas de Mercado

Mexican Demand Indicators Show Signs of Life -- Market Talk

4 jun 2026, 20:15 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4 jun 2026, 19:46 UTC

Charlas de Mercado

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4 jun 2026, 19:38 UTC

Charlas de Mercado

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4 jun 2026, 19:30 UTC

Charlas de Mercado

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4 jun 2026, 18:47 UTC

Adquisiciones, fusiones, absorciones

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4 jun 2026, 18:38 UTC

Ganancias

Money Quote: Tech Weakness in Context -- WSJ

4 jun 2026, 18:24 UTC

Ganancias

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4 jun 2026, 17:09 UTC

Charlas de Mercado

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4 jun 2026, 16:58 UTC

Ganancias

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4 jun 2026, 16:46 UTC

Charlas de Mercado

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4 jun 2026, 16:38 UTC

Ganancias

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4 jun 2026, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

4 jun 2026, 16:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

4 jun 2026, 16:13 UTC

Charlas de Mercado

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4 jun 2026, 16:11 UTC

Charlas de Mercado

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4 jun 2026, 15:56 UTC

Charlas de Mercado

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Comparación entre iguales

Cambio de precio

Pharma Mar SA previsión

Precio Objetivo

By TipRanks

27.25% repunte

Estimación a 12 Meses

Media 120.502 EUR 27.25%

Máximo 121 EUR

Mínimo 120 EUR

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Pharma Mar SA Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

Comprar

Mantener

Vender

De acuerdo con 2 analistas que ofrecen calificaciones bursátiles a para Pharma Mar SA Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Pharma Mar SA

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.